Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Glesatinib |
| Trade Name | |
| Synonyms | MGCD-265|MGCD 265 |
| Drug Descriptions |
Glesatinib (MGCD265) inhibits several tyrosine kinases including MET (type II inhibitor), MST1R (RON), and AXL, as well as VEGFR1-3, and TIE2, which may result in decreased tumor growth (PMID: 25806189, PMID: 26555154, PMID: 32306194). |
| DrugClasses | AXL Inhibitor 30 MET Inhibitor 59 RON Inhibitor 11 VEGFR Inhibitor (Pan) 36 |
| CAS Registry Number | 936694-12-1 |
| NCIT ID | C77876 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Docetaxel + Glesatinib | Docetaxel Glesatinib | 0 | 1 |
| Erlotinib + Glesatinib | Erlotinib Glesatinib | 0 | 1 |
| Glesatinib | Glesatinib | 0 | 2 |
| Glesatinib + Nivolumab | Glesatinib Nivolumab | 0 | 1 |